 Chiasma Inc NASDAQ: CHMA has presented patient-reported outcomes PROs data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone. Data demonstrated that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs iSSAs to Mycapssa. 